April 2005
Investment Dealers' Digest;4/25/2005, Vol. 71 Issue 16, p48
Trade Publication
The article presents information on investment banking in the field of healthcare as of April 2005. Allion Healthcare, a specialty pharmacy and disease management service focused on patients with HIV and AIDS, filed for an Initial Public Offering that seeks to raise up to $57.5 million. Johnson & Johnson Inc. said that its Ortho-McNeil unit will pay $245 million in cash to buy Peninsula Pharmaceutical, a privately held antibiotic developer. The Alameda, California-based Peninsula had been scheduled to go public in February 2005, but the offering was pulled when an undisclosed suitor come forward. INSET: In The News.


Related Articles

  • Regenerative medicine - A new paradigm in human health. Bhuller, Rhenu // Australasian Biotechnology;Sep2015, Vol. 25 Issue 3, p19 

    The article offers the author's insights regarding the benefits offered by regenerative medicine in terms of treating unmet medical needs and treatment cost. Topics discussed include advancement in regenerative medicine such as stem cell therapy and therapies which combine genetic, immunology,...

  • Editorial. Lerer, Leonard // Journal of Medical Marketing;Sep2007, Vol. 7 Issue 4, p273 

    The author offers his thoughts on health marketing. He said that a meeting of pharmaceutical, biotechnology, medical device and marketing managers sponsored by the INSEAD Healthcare Management Initiative (HMI) and Johnson & Johnson on March 9, 2007 reflected the current state of health...

  • Allion Healthcare to be Bought by HIG. Marino, Jonathan // Mergers & Acquisitions Report;10/26/2009, Vol. 22 Issue 43, p17 

    The article reports on the agreement of private equity firm HIG Capital to acquire Allion Healthcare Inc., a provider of specialty pharmacy and disease management services for ailments including AIDS. The deal is valued at about 278 million dollars, with HIG paying 6.60 dollars per share of...

  • Broad spectrum of responsibilities ensures J&J's health. Ceniceros, Roberto // Business Insurance;4/26/2010, Vol. 44 Issue 17, p32 

    The article features Scott P. Borup, director of corporate risk management at New Brunswick, New Jersey-based health care products and pharmaceutical manufacturer Johnson & Johnson and Risk Management Honor Roll 2010 member in the U.S. His tasks range from settling a property damage claim in...

  • Schizophrenia Update.  // PharmaWatch: CNS;January 2004, Vol. 3 Issue 1, p7 

    Reports on pharmaceutical developments about schizophrenia from November 15 to December 14, 2003. Findings of a study showing the reduction of cost of care in patients who use Johnson & Johnson Inc.'s antipsychotic for schizophrenia; Repligen's phase II trial of secretin in refractory schizophrenia.

  • Johnson & Johnson.  // Global Cosmetic Industry;Aug2007, Vol. 175 Issue 8, p80 

    The article forecasts the sales performance of Johnson & Johnson Inc. in the U.S. It could be noted that the company holds top spots in the medical devices market and pharmaceutical markets. More than 40 percent of its revenue is generated by its pharmaceutical group. It is predicted that its...

  • COMPANY SPOTLIGHT -- Johnson & Johnson.  // PharmaWatch: CNS;September 2004, Vol. 3 Issue 9, p19 

    Focuses on Johnson and Johnson Inc., a global manufacturer of health care products as well as a provider of related health services. Product lines; Familiar brand names; Well-known brands within the company's portfolio.

  • COMPANY SPOTLIGHT -- Johnson & Johnson.  // PharmaWatch: Cancer;Jun2005, Vol. 4 Issue 6, p21 

    The article highlights the Johnson and Johnson (J&J) pharmaceutical company. J&J is a global manufacturer of health care products and provider of related health services. It has collaborated with Millennium Pharmaceuticals for the phase II clinical trial of the anticancer drug, Velcade, for...

  • Johnson & Johnson JNJ. Brilliant, Heather // Morningstar StockInvestor;6/15/2007, Vol. 6 Issue 12, p6 

    The article presents a profile of Johnson & Johnson (J&J) and offers information on its stock's performance. The author believes that the company, drawing more than 40% of its revenues from its pharmaceutical group, faces competition for its drugs from other branded products and generic...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics